- Home
- TAP vs DNTH Comparison
TAP vs DNTH Comparison
Compare TAP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAP | DNTH |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TAP | DNTH |
|---|---|---|
| Price | $38.95 | $74.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 17 |
| Target Price | $44.52 | ★ $140.80 |
| AVG Volume (30 Days) | ★ 3.0M | 901.0K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $11,723,800,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.07 | N/A |
| P/E Ratio | $19.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.52 | $32.28 |
| 52 Week High | $54.82 | $117.88 |
Technical Indicators
Market Signals| Indicator | TAP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 18.89 |
| Support Level | $38.12 | $68.85 |
| Resistance Level | $43.69 | $92.81 |
| Average True Range (ATR) | 0.94 | 3.51 |
| MACD | 0.39 | -0.83 |
| Stochastic Oscillator | 74.27 | 14.86 |
Price Performance
Historical ComparisonAbout TAP Molson Coors Beverage Company Class B
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume in the US, Canada, and the United Kingdom. Through licensing agreements, it also brews and distributes beer and nonbeer beverage categories under partner brands from Heineken, Anheuser-Busch InBev, Asahi, Fever-Tree, and Coca-Cola. North America remains its largest market, accounting for nearly 80% of total revenue.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.